Windward Bio secured $165 million to fund clinical trials in asthma, COPD, and additional respiratory and dermatology indications. The company’s long-acting antibody programs are positioned to provide dosing advantages over existing biologic medicines, targeting inflammatory pathways relevant to chronic respiratory disease. The financing expands runway for development and supports execution across multiple studies, which can be critical for maintaining momentum after early efficacy signals. It also increases competitive pressure on companies pursuing long-interval biologics to improve adherence and reduce treatment burden. For biotech investors, a $165 million round emphasizes that respiratory immunology remains an area where investors see clear differentiation opportunities in sustained exposure and manageable safety profiles.